As others stated, this is really a PR piece.
The study aim was to see what the tolerable dose for a future study might be. 17 patients ranging from metastatic breast ca to unresectable colon ca were studied from 2014-2016.
Patients were given either 500, 1000, or 2000mg of what must be a truly horrible liquid to drink and then watched for adverse outcomes.
Most patients discontinued treatment due to disease progression, and patients in the 2000mg dosage group had trouble tolerating the medication.
Anyway, not to knock the study, hope things pan out, but to market this as the "achilles heel of cancer" is, well, a bit hard to swallow.